146
Participants
Start Date
April 30, 2005
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
Mupirocin Ointment [Treatment]
The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
Polyethylene Glycol Ointment [Placebo]
The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
VA Ann Arbor Healthcare System, Ann Arbor
University of Michigan
OTHER
Trinity Health Michigan
OTHER
US Department of Veterans Affairs
FED